Joranger, Paal http://orcid.org/0000-0001-6274-8039
Nesbakken, Arild
Sorbye, Halfdan
Hoff, Geir
Oshaug, Arne
Aas, Eline
Article History
Received: 7 December 2018
Accepted: 24 October 2019
First Online: 9 November 2019
Compliance with ethical standards
:
: All authors contributed to the work, are aware of, and agree to the submission. Any other person or body with an interest in the manuscript, such as our funders and employers, are also aware and agreed on the submission. Paal Joranger, Eline Aas, and Arne Oshaug declare no support from any organisation for the submitted work, no financial relationships in the previous 3 years with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work. In 2017, Geir Hoff received payment from Amgen Norway for giving a lecture at a medical conference. Halfdan Sorbye received Grants and personal fees from Merck, Roche, and Amgen and personal fees from Sanofi during the study. Arild Nesbakken received funding from Helse Sør-Øst for the clinical studies on colorectal cancer (OUS-Aker series). He is a member of a research group in OUS, which has patents on one diagnostic and two prognostic genetic tests for colorectal cancer. He received payment from Amgen Norway for giving a lecture at a medical conference 2018. Financial support for this study was provided entirely by the authors’ employers, which are listed above. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the article. The authors declare that they have no competing interests.
: The observational study from 1993 to 2010, including 2049 patients diagnosed with CRC at Oslo University Hospital, was approved by the Regional Ethics Committee (Norway) for Medical Research (REK approval 1.2005.1629). The study with data collected from the National Patient Register (NPR) was approved by the Regional Ethics Committee (Norway). The reference number is S-02113 (2013/83).